Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Level 5 - mechanism / opinion, no new human data
Expert opinion and narrative commentary without new human clinical data presented in the text.
OpenAlex W4366742421 · doi:10.1080/13543784.2023.2206560
What was done
This expert opinion commentary evaluated the findings of a multiple-ascending dose phase 1b clinical trial investigating retatrutide (LY3437943), a triple agonist of GLP-1, GIP, and glucagon receptors, in participants with type 2 diabetes.
What was found
The abstract reports no numerical values, exact effect sizes, or statistical figures. Qualitatively, retatrutide was described as relatively safe with pharmacokinetic characteristics supporting once-weekly dosing, with potential reductions in plasma glucose and body weight relative to dulaglutide.
Why it matters
As a novel triple-receptor agonist, retatrutide could offer expanded therapeutic options for diabetes and obesity, though its distinct contribution beyond dual agonists or potent GLP-1 agonists requires head-to-head evaluation against semaglutide and tirzepatide.
Limits
This is an expert review rather than a primary trial report; no sample sizes, specific quantitative endpoints, or adverse event rates are provided in the abstract. Evidence is constrained by reliance on early-phase (phase 1b) data, requiring confirmation in larger, long-term studies.
Cited by
- supports The developmental patent and intellectual property rights for the multi-receptor agonist retatrutide are owned solely by Eli Lilly.